StockNews.com Initiates Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)
Research analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) in a note issued to investors on Friday. The firm set a “buy” rating on the biotechnology company’s stock. Separately, Mizuho reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the […]
Research analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) in a note issued to investors on Friday. The firm set a “buy” rating on the biotechnology company’s stock. Separately, Mizuho reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the […]
